<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04179045</url>
  </required_header>
  <id_info>
    <org_study_id>BXA 2019001</org_study_id>
    <nct_id>NCT04179045</nct_id>
  </id_info>
  <brief_title>A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System</brief_title>
  <official_title>A Registry Trial of the Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System in Patients With Coronary Artery Disease: BIOHEART Ⅲ</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Bio-heart Biological Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CCRF Inc., Beijing, China</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Bio-heart Biological Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, multi-center single arm registry trial, planning to enroll 785&#xD;
      subjects. All subjects will receive clinical follow-up at 1 month, 6 month, 9 month and 1, 2,&#xD;
      3, 4, 5 year after index procedure. The primary endpoint will be target lesion failure (TLF)&#xD;
      at 1 year after index procedure,which will be analyzed to evaluate the efficacy and safety of&#xD;
      the device.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TLF</measure>
    <time_frame>1 year after index procedure</time_frame>
    <description>Target lesion failure, consists of cardiac death, MI attributed to the target vessel, and ischemic driven - target lesion revascularization (ID-TLR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The device-oriented composite（DoCE） / TLF</measure>
    <time_frame>at 1, 6, 9 month and 1, 2, 3, 4, 5 year after index procedure</time_frame>
    <description>consists of cardiac death, MI attributed to the target vessel, and ischemic driven- target lesion revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The patient-oriented composite（PoCE）</measure>
    <time_frame>at 1, 6, 9 month and 1, 2, 3, 4, 5 year after index procedure</time_frame>
    <description>includes all-cause mortality, any MI, and any revascularization. Death（Cardiac death，Vascular death，Non-cardiovascular death）; Myocardial Infarction (target vessel MI, non-target vessel MI); Target lesion Revascularization（ischemic driven, non-ischemic driven） target vessel Revascularization （ischemic driven, non-ischemic driven）; Any Revascularization （ischemic driven, non-ischemic driven）.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis（ARC）</measure>
    <time_frame>at 1, 6, 9 month and 1, 2, 3, 4, 5 year after index procedure</time_frame>
    <description>Timing：Acute, Subacute, Late,Very late stent thrombosis Definite and Probable Stent Thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>immediately after index procedure</time_frame>
    <description>defined as attainment of residual stenosis less than 30% by visual estimation and TIMI flow grade 3 post stent implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion success</measure>
    <time_frame>immediately after index procedure</time_frame>
    <description>defined as attainment of diameter residual stenosis less than 30% by visual estimation and TIMI flow grade 3, after the target lesion treated by any PCI methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success</measure>
    <time_frame>up to 7 days after index procedure</time_frame>
    <description>defined as attainment of lesion success and without any major adverse cardiac events during hospitalization (up to 7 days after index procedure)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">785</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Bioheart</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects have CAD with one or two de novo native coronary artery lesions and will be treated with Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System. There will be only one arm in this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System</intervention_name>
    <description>Subjects enrolled will be treated with Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent.</description>
    <arm_group_label>Bioheart</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General Inclusion Criteria:&#xD;
&#xD;
          1. Age from 18 to 75 years old, man or non-pregnant woman.&#xD;
&#xD;
          2. Subjects with asymptomatic ischemic evidence, stable or unstable angina, or old&#xD;
             myocardial infarction, are suitable for selective PCI.&#xD;
&#xD;
          3. Subjects without contraindications of coronary artery bypass grafting (CABG).&#xD;
&#xD;
          4. Subjects are able to understand the purpose of this study, volunteer to participate&#xD;
             and sign informed consent.&#xD;
&#xD;
        Angiographic Inclusion Criteria:&#xD;
&#xD;
          1. One or two de novo target lesions&#xD;
&#xD;
               1. If subject has only one target lesion, the second non-target lesion must be&#xD;
                  treated but the non-target lesion must be present in a different epicardial&#xD;
                  vessel; the non target lesion must be treated first and successfully prior to the&#xD;
                  subjects' register.&#xD;
&#xD;
               2. If there are two target lesions, they must be present in different epicardial&#xD;
                  vessels.&#xD;
&#xD;
               3. The definition of epicardial vessels means the left anterior descending artery&#xD;
                  (LAD), the left circumflex artery (LCX), and the right coronary artery (RCA) and&#xD;
                  their branches. Thus, for example, the subject must not have lesions requiring&#xD;
                  treatment in both the LAD and a branch.&#xD;
&#xD;
          2. Target lesion diameter stenosis is estimated visually ≥ 70% (or ≥ 50% with clinical&#xD;
             evidence of myocardial ischemia), with TIMI flow grade ≥1; Target lesion length ≤24mm&#xD;
             (visually); target lesion diameter between ≥2.5 mm to ≤ 4.00 mm.&#xD;
&#xD;
          3. Each target lesion must be covered completely by one scaffold.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          1. Any newly onset acute myocardial infarction within 1 week or, myocardial enzymes does&#xD;
             not return to normal level after myocardial infarction.&#xD;
&#xD;
          2. Target vessel has been implanted with stents within 1 year before procedure.&#xD;
&#xD;
          3. Subjects with severe heart failure (≥ grade III NYHA) or left ventricular ejection&#xD;
             fraction &lt;35% (accessed by ultrasound or left ventricular angiography).&#xD;
&#xD;
          4. subject with severe kidney functional damaged before procedure: serum creatinine&gt;2.0mg&#xD;
             /dl (176.8μmol / L) or subject is receiving hemodialysis.&#xD;
&#xD;
          5. Subjects with high bleeding risk, with active gastrointestinal ulcers, history of&#xD;
             cerebral hemorrhage or history of subarachnoid hemorrhage, history of ischemic stroke&#xD;
             within the past six months, with contraindications of anti-platelet agents and&#xD;
             anticoagulants, and subjects cannot receive antithrombolytic therapy.&#xD;
&#xD;
          6. subject is known hypersensitive or allergic to aspirin, clopidogrel, heparin, contrast&#xD;
             agent, polylactic acid polymer and rapamycin.&#xD;
&#xD;
          7. The subject's life expectancy is less than 24 months.&#xD;
&#xD;
          8. Subjects is currently participating in other drug or medical device clinical trial&#xD;
             that has not yet completed its primary endpoint .&#xD;
&#xD;
          9. Subjects have received any solid organ transplants or are ready to undergo organ&#xD;
             transplant.&#xD;
&#xD;
         10. Subjects have unstable arrhythmia, such as high-risk ventricular premature beats, and&#xD;
             ventricular tachycardia.&#xD;
&#xD;
         11. Subjects receive chemotherapy for tumor.&#xD;
&#xD;
         12. Subjects have received or planning to receive coronary or chest radiotherapy.&#xD;
&#xD;
         13. Subjects with Immunosuppressive, autoimmune diseases, have planned to receive or&#xD;
             underwent immunosuppressive therapy.&#xD;
&#xD;
         14. Subjects have planned to receive or are receiving long-term anticoagulation therapy,&#xD;
             such as heparin, warfarin and so on.&#xD;
&#xD;
         15. Subjects have planned to receive selective surgery within 6 months, which requires&#xD;
             them to discontinue aspirin or clopidogrel.&#xD;
&#xD;
         16. Blood tests showed that the platelet count is less than 100 × 10^9 / L, or more than&#xD;
             700 × 10^9 / L, the white blood cells count is less than 3 × 10^9 /L.&#xD;
&#xD;
         17. subject with diagnosed or suspected liver cirrhosis.&#xD;
&#xD;
         18. Subjects with diffuse peripheral vascular disease, that precludes safe 6 French sheath&#xD;
             insertion.&#xD;
&#xD;
        Angiographic exclusion criteria:&#xD;
&#xD;
        These exclusion criteria apply to the target or non-target lesion(s), target or non-target&#xD;
        vessel(s):&#xD;
&#xD;
          1. Target or non-target lesion(s) located in left main.&#xD;
&#xD;
          2. Subjects with triple vessel lesion in LAD, LCX or RCA, which all need to be treated.&#xD;
&#xD;
        These exclusion criteria apply to the target lesion(s) or target vessel(s):&#xD;
&#xD;
          1. Target lesion located in left main.&#xD;
&#xD;
          2. Target lesion located in the aorto-ostial of RCA (within 3 mm of the origin of the&#xD;
             RCA).&#xD;
&#xD;
          3. Target lesion located within 3 mm of the origin of the LAD and LCX.&#xD;
&#xD;
          4. Lesion involving a bifurcation with a:&#xD;
&#xD;
               1. Side branch ≥ 2.5 mm in diameter, or&#xD;
&#xD;
               2. Side branch with diameter stenosis ≥ 50%, or&#xD;
&#xD;
               3. Side branch requiring protection guide wire, or&#xD;
&#xD;
               4. Side branch requiring pre-dilatation.&#xD;
&#xD;
          5. Anatomy proximal to or within the lesion that may affect delivery of the Bioheart,&#xD;
             including:&#xD;
&#xD;
               1. Extreme angulation (≥ 90°) proximal to or within the target lesion, or&#xD;
&#xD;
               2. Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion,&#xD;
                  or&#xD;
&#xD;
               3. Moderate or heavy calcification proximal to or within the target lesion.&#xD;
&#xD;
          6. Target lesion involves a myocardial bridge.&#xD;
&#xD;
          7. Target vessel contains thrombus as indicated in the angiographic images or IVUS.&#xD;
&#xD;
          8. Prior to the index procedure target vessel has been previously treated with a stent at&#xD;
             any time such that the Bioheart stent would need to cross the stent to reach the&#xD;
             target lesion.&#xD;
&#xD;
          9. Target vessel has been previously treated with a stent and the target lesion is within&#xD;
             5 mm proximal to a previously treated lesion.&#xD;
&#xD;
         10. Target lesion cannot meet the following outcomes, after the complete balloon&#xD;
             pre-dilatation:&#xD;
&#xD;
               1. Residual (DS %) is &lt; 40% (per visual estimation), ≤ 20% is strongly recommended;&#xD;
&#xD;
               2. TIMI Grade-3 flow (per visual estimation);&#xD;
&#xD;
               3. No angiographic complications (e.g., no-reflow, distal embolization, side branch&#xD;
                  closure)&#xD;
&#xD;
               4. No dissections NHLBI grade D-F;&#xD;
&#xD;
               5. No chest pain lasting &gt; 5 minutes, and;&#xD;
&#xD;
               6. No ST depression or elevation lasting &gt; 5 minutes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guosheng Fu, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guosheng Fu, Professor</last_name>
    <phone>0086-0571-86006246</phone>
    <email>fugs@medmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>chengjun Guo, Professor</last_name>
      <email>spnie@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Chengjun Guo, professor</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>BeijingChao-YangHospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lefeng Wang, professor</last_name>
      <email>wlf311@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuqing Hou, Professor</last_name>
      <email>hyq@fimmu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taida International Cardioascular Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Feng Zhang, Professor</last_name>
      <email>zfwh909@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang UniversitySchool of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guosheng Fu, Professor</last_name>
      <phone>0086- 0571-86006246</phone>
      <email>fugs@medmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioresorbable Vascular Scaffold System</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

